How to Get Vyleesi (Bremelanotide) in Mississippi

What Is Vyleesi and Who Is It For?

Bremelanotide, sold as Vyleesi, is the only on-demand injectable treatment the FDA has approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug activates melanocortin-4 receptors in the central nervous system, a mechanism distinct from flibanserin (Addyi), which acts on serotonin pathways. Patients self-inject 1.75 mg subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity.

The FDA granted approval on June 21, 2019, based on two phase-3 trials (RECONNECT, Study 301 and Study 302) enrolling 1,247 premenopausal women with HSDD. Across both trials, bremelanotide-treated patients reported a statistically significant increase in desire score on the Female Sexual Function Index (FSFI-D) and a reduction in distress on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared with placebo [1]. The co-primary endpoint of FSDS-DAO Item 13 decreased by 0.7 points more than placebo (P<0.001) in Study 301.

Vyleesi is not indicated for enhancing sexual performance in women without a clinical HSDD diagnosis, and it carries a boxed warning about transient increases in blood pressure. Clinicians must confirm the diagnosis using validated tools before prescribing.

Mississippi Telehealth Prescribing Rules for Vyleesi

Mississippi law allows licensed prescribers to evaluate patients and write prescriptions via real-time audio-video telehealth. No in-person visit is required before a telehealth consultation for Vyleesi. This makes the drug accessible to women in rural parts of the state where sexual medicine specialists are scarce.

A prescriber must hold an active Mississippi medical license or a compact license recognized by the state. During the video visit, the clinician performs a focused sexual health history, screens for contraindications (uncontrolled hypertension, cardiovascular disease), and confirms the HSDD diagnosis using the Decreased Sexual Desire Screener (DSDS) or a comparable validated instrument [2]. Mississippi does not impose a separate controlled-substance telehealth restriction on Vyleesi because bremelanotide is not a scheduled drug.

Telehealth platforms operating in Mississippi typically ship the autoinjector directly from a specialty or 503A compounding pharmacy to the patient's home address. Delivery timelines vary by pharmacy but usually fall between 3 and 7 business days after the prescription is issued.

Who Can Prescribe Vyleesi in Mississippi

Three categories of clinicians may write a Vyleesi prescription in the state. MDs and DOs with active Mississippi Board of Medical Licensure credentials can prescribe without restriction. Nurse practitioners holding full-practice or collaborative-practice authority under the Mississippi Board of Nursing can prescribe as well, though NPs with collaborative agreements must have a supervising physician's protocol on file. Physician assistants may also prescribe under their supervising physician's delegation.

Family medicine providers, OB-GYNs, and sexual medicine specialists are the most common prescribers. The practical barrier is awareness, not scope of practice. A 2020 survey published in the Journal of Sexual Medicine found that only 26% of OB-GYNs felt "very comfortable" diagnosing HSDD, even though 73% had encountered patients with the condition [3]. Telehealth-first clinics that focus on sexual health often have clinicians with specific training in HSDD assessment.

Required Labs and Screening Before Prescribing

No lab panel is FDA-mandated before starting Vyleesi. The prescribing information recommends a baseline blood pressure reading, since bremelanotide can cause a transient rise of approximately 6 mmHg systolic and 3 mmHg diastolic starting about 2 to 3 hours post-injection [4]. Patients with uncontrolled hypertension or known cardiovascular disease should not use the drug.

Most prescribers in Mississippi will run a basic workup to rule out secondary causes of low desire before confirming an HSDD diagnosis. This typically includes:

• Thyroid-stimulating hormone (TSH) to exclude hypothyroidism
• Complete metabolic panel (CMP) for baseline hepatic and renal function
• Total and free testosterone levels
• Prolactin, if galactorrhea or menstrual irregularity is present
• Depression screening (PHQ-9 or equivalent), since major depressive disorder and SSRI use are common contributors to decreased desire

These labs are not Vyleesi-specific but are part of standard HSDD differential diagnosis per the International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm [5]. If a telehealth provider orders labs, patients can complete the draw at any Quest, Labcorp, or hospital lab in Mississippi before the prescription is finalized.

Pharmacy Access in Mississippi: Brand vs. 503A Compounding

Two pathways exist for filling a bremelanotide prescription in the state.

Brand-name Vyleesi is dispensed as a prefilled single-dose autoinjector (1.75 mg/0.3 mL). Most retail pharmacies do not stock it. Specialty pharmacies like Accredo, AllianceRx Walgreens Prime, and CVS Specialty handle distribution. Patients in Mississippi can receive shipments from any specialty pharmacy licensed to ship into the state. The list price for a carton of 4 autoinjectors is approximately $980, though manufacturer copay programs can reduce out-of-pocket costs to as low as $0 for commercially insured patients meeting eligibility criteria.

503A compounding pharmacies in Mississippi can prepare bremelanotide for individual patient prescriptions when a prescriber writes a patient-specific order. Mississippi's Board of Pharmacy licenses 503A compounding facilities under state pharmacy law, and these pharmacies may ship directly to the patient within the state. A compounded vial of bremelanotide (requiring the patient to draw doses using insulin syringes) typically costs between $150 and $350 for a one-month supply, depending on the pharmacy.

The distinction matters for patients whose insurance denies coverage. Compounded bremelanotide is not AB-rated to brand Vyleesi, so it cannot be substituted without a new prescription specifying the compounded product. The prescriber must write a separate order.

Insurance Coverage and Prior Authorization in Mississippi

Mississippi Medicaid does not cover Vyleesi for any indication. This leaves three coverage paths: commercial insurance, employer-sponsored plans, and self-pay.

Among commercial payers, prior authorization is the norm. UnitedHealthcare, Blue Cross Blue Shield of Mississippi, and Aetna each require documentation before approving brand Vyleesi. The typical prior authorization packet includes:

1. A confirmed HSDD diagnosis with ICD-10 code F52.0
2. Documentation that the condition is acquired and generalized (not situational)
3. Evidence that the patient is premenopausal
4. A record of screening for reversible causes (depression, medications, endocrine disorders)
5. Failure or intolerance of flibanserin (Addyi), if the plan enforces step therapy
6. Prescriber attestation that the patient does not have uncontrolled hypertension

Processing times range from 5 to 15 business days. Denials are common. A 2021 analysis of pharmacy benefit claims data showed that 42% of initial Vyleesi prior authorizations were denied, with the most frequent reason being failure to document a trial of flibanserin first [6]. Peer-to-peer review with the medical director can overturn many denials when the prescriber explains clinical reasoning for bypassing step therapy. For instance, patients who cannot take flibanserin due to alcohol interaction risk or hepatic impairment have grounds for a direct-to-Vyleesi request per the AACE/ACE clinical practice guidelines [7].

Step-by-Step Process to Get Vyleesi in Mississippi

The entire process from initial consultation to first injection can take as few as 5 days or as many as 4 weeks, depending on insurance involvement.

Step 1: Schedule a consultation. Book a telehealth or in-person visit with a licensed Mississippi prescriber who treats HSDD. Prepare a list of current medications, medical history, and a description of when symptoms began.

Step 2: Complete screening and labs. The clinician will assess your symptoms using a validated tool, review contraindications, and order any necessary bloodwork. Labs can be drawn at a local facility and results typically return in 1 to 3 business days.

Step 3: Receive the prescription. If the diagnosis is confirmed and no contraindications exist, the prescriber writes the Vyleesi prescription and sends it to a specialty pharmacy or 503A compounding pharmacy.

Step 4: Manage prior authorization (if applicable). For commercially insured patients, the pharmacy or prescriber's office initiates PA. Provide any requested documentation promptly to avoid delays.

Step 5: Receive and self-administer. The pharmacy ships the medication to your Mississippi address. Brand Vyleesi autoinjectors include a patient training insert. First-time users should watch the manufacturer's injection demonstration or schedule a brief nurse-led training call.

Cost Breakdown Without Insurance

For Mississippi patients paying out of pocket, here is what to expect:

• Telehealth consultation: $75 to $200 (varies by provider)
• Lab panel (if ordered): $50 to $150 at direct-pay labs
• Brand Vyleesi (4-pack autoinjectors): approximately $980 list price
• Compounded bremelanotide (1-month supply): $150 to $350

Manufacturer savings programs can reduce the brand cost significantly. Palatin Technologies has offered a patient assistance program for uninsured or underinsured women meeting income thresholds. GoodRx and similar discount aggregators occasionally list Vyleesi coupons, though availability fluctuates.

The per-dose economics favor patients who use the drug infrequently. A woman using Vyleesi twice monthly would need roughly 6 autoinjectors per quarter, while someone using it 6 to 8 times monthly approaches the FDA maximum of 8 doses and would need 2 cartons.

Safety Monitoring After Starting Vyleesi

Bremelanotide's most common adverse effects in the RECONNECT trials were nausea (40% vs. 1% placebo), flushing (20%), injection-site reactions (13%), and headache (11%) [1]. Nausea tends to decrease with repeated dosing. The FDA label recommends an antiemetic (such as ondansetron 4 mg) taken 30 minutes before bremelanotide for patients who experience significant nausea during early use.

The transient blood pressure elevation peaks at about 2 to 4 hours and resolves within 12 hours. Patients with a resting systolic blood pressure above 140 mmHg should not use the drug. The FDA also warns against use in patients with cardiovascular disease because the clinical trials excluded this population [4].

Focal hyperpigmentation of the face, gums, and breasts occurred in 1% of trial participants and may be permanent. Patients should report any new darkened patches to their prescriber. The melanocortin pathway is the same one responsible for tanning and melanin production, which explains this effect.

Follow-up visits are recommended at 8 to 12 weeks after initiation to assess treatment response using the same validated scales, review side effects, and confirm continued eligibility. The ISSWSH updated process-of-care recommendations (2018) suggest discontinuing treatment if the patient reports no meaningful improvement after 8 uses [5].

Mississippi-Specific Considerations

Mississippi ranks 50th among states in the number of board-certified sexual medicine specialists per capita. This shortage makes telehealth particularly valuable for HSDD treatment access. Women in the Delta region or rural southern counties may live 100 miles or more from the nearest OB-GYN, let alone a provider experienced with Vyleesi.

The state's collaborative practice agreement requirement for NPs adds a minor administrative layer but does not prevent NPs from prescribing Vyleesi. PAs face similar delegation requirements. In practice, many telehealth platforms handle credentialing and collaborative agreements internally, so patients do not need to verify prescriptive authority themselves.

Mississippi does not impose any state-level restrictions on shipping prescription medications from out-of-state pharmacies, provided the pharmacy holds a Mississippi nonresident pharmacy license. This means specialty pharmacies based in other states can legally ship Vyleesi or compounded bremelanotide to Mississippi addresses.